https://doi.org/10.31705/BPRM.v5(1).2025.11

"How Much Is Too Much": *Towards a Standardised Threshold for Genomic Instability of Stem Cells for Clinical and Research Application*

1. Background

Stem cells are the body's master cells with a unique ability to develop into many different types of cells—such as heart, nerve, or skin cells—making them vital in early development, tissue repair, and medical treatments. Researchers investigate stem cells for regenerative medicine, drug development, and disease research due to their unique properties. There are two main categories of stem cells: Embryonic Stem Cells (ESC) and Adult Stem Cells (ASC). Stem cells can divide indefinitely, remaining undifferentiated or differentiating into specific cell types[1].



Figure 1: Different types of stem cells and their origins

As shown in Figure 1, human ESC from the blastocyst's inner cell mass can develop into all cell types of the three germ layers. ASCs are found in various body niches as alternative sources of quiescent progenitors for tissue maintenance and regeneration.

In 2006, Takahashi and Yamanaka demonstrated the potential to reprogram somatic cells into an embryonic-like state through the ectopic co-expression of specific transcription factors. They induced pluripotent stem cells (iPSCs) from adult fibroblasts by introducing four co-factors under embryonic stem cell culture conditions[2].

Genomic instability in stem cells raises concerns for their function and clinical application, with recent data showing variable and time-dependent genetic abnormalities that impair stability. Genomic and epigenomic instability is a hallmark of cancer cells, jeopardising the safety of stem cell therapies. Currently, the mechanisms by which these alterations affect cellular behaviour are poorly understood. Establishing acceptable genomic instability levels is a critical challenge. All stem cells carry some genomic change risk, but identifying the threshold for problematic instability is crucial for effective application.

This text reviews ongoing efforts and suggests strategies to standardise acceptable thresholds for genomic instability in stem cells, focusing on clinical and research implications.

2. Mechanisms of Genomic Instability

Genomic instability in stem cells refers to the propensity for genetic changes, including chromosomal abnormalities, copy number variations (CNVs), point mutations, and epigenetic modifications such as DNA methylation and Histone modifications. Instability can arise spontaneously or due to external factors such as cell culture conditions, reprogramming methods, and passaging. ESCs and iPSCs are particularly susceptible due to their high proliferative capacity and the stresses of reprogramming and long-term culture. Frequent genomic alterations, including trisomy of chromosomes 12, 17 and gains at 20q11.21, raise concerns about clinical implications. The International Stem Cell Initiative studied karyotypes of 120 ESC lines globally and found that most abnormal cultures were mosaic, showing abnormalities in chromosomes 1, 12, 17, and 20.ESC lines are subjected to a highly dynamic stage of development, with significant epigenetic modifications that contribute to gene expression regulation[3].

Understanding genomic instability mechanisms is crucial for mitigating risks. Thus, managing genomic stability is vital for safely translating stem cell technologies into clinical and therapeutic settings.

3. Why a Threshold Matters

Setting standardised thresholds for genomic instability is crucial for safety, therapeutic effectiveness, and consistency in clinical and research settings. Without clear thresholds, stem cells with minor but significant genetic alterations could be inadvertently used in therapies, leading to risks like developing malignancies. It supports regulatory oversight, ensuring global compliance in stem cell applications. From a research standpoint, established stability standards improve reproducibility and foster confidence in data, encouraging effective collaborations.

4. Efforts to Standardize Thresholds for Genomic Instability in Stem Cells

Despite progress in stem cell biology, defining standardised thresholds for acceptable genomic instability in stem cells remains challenging. Various proposals have been made to address this issue:

4.1 Absence of a Defined Safe Passage Threshold:

Large-scale analyses show genomic aberrations in human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) can occur at any culture stage, complicating efforts to set a universal threshold for acceptable instability. Notably, the International Stem Cell Initiative observed that 23% of initially normal ESC lines developed abnormalities over time[4].

4.2 Quality Control Guidelines and Initiatives:

Global regulatory agencies recommend rigorous cytogenetic analysis, telomerase activity assessment, and evaluations of cell proliferation and senescence to maintain genomic integrity. They also propose international meetings with regulatory authorities, researchers, pharmaceutical companies, and patient advocacy groups to establish standardised regulatory frameworks[5].

5. Proposed framework for Threshold Standardization

A standardised framework for acceptable genomic instability in stem cells could effectively address current inconsistencies and enhance the practical utility of stem cells in therapeutic and research applications. This framework can be structured into three key components as shown in Figure 2:



Figure 2: Proposed framework for threshold standardization

5.1 Risk-Based Stratification

Establish clear categories for genomic changes that pose serious clinical or functional risks versus those that are likely harmless. Significant alterations, like oncogene amplifications or mutations disabling tumour suppressors, need strict control. Conversely, some common mutations influenced by culture may be more accepted.

5.2 Application-Specific Thresholds

Different stem cell applications require distinct stability criteria. Therapeutic applications demand stringent standards of genomic integrity to minimise risks to patients. In contrast, applications involving in vitro disease modelling or drug screening may adopt slightly more flexible thresholds, as long as the genomic variations do not significantly impact the model's validity or reproducibility.

5.3 Standardized Screening Panels

Define a minimal yet comprehensive panel of genomic alterations to monitor across all laboratories routinely. This panel should include frequently reported alterations such as amplifications at 20q11.21, trisomy 12, and commonly observed hotspot mutations like TP53. Advanced genomic assessment tools, such as next-generation sequencing (NGS) and digital droplet PCR (ddPCR), ought to be incorporated into routine practices alongside cytogenetic methods.

6. Conclusion

The proposed framework for standardizing genomic instability and its components will systematically improve the safety of therapeutic stem cells and the reliability of research outcomes. Future research should focus on large-scale studies to evaluate the long-term effects of genomic instability in stem cells. Developing computational models and bioinformatics tools will improve predictions about the clinical significance of genomic changes. International collaboration is essential to harmonise regulations and create global stem cell registries to achieve consensus and standardisation.

References:

[1] Junwei Liu and Cuihua Cao, 'Clinical Application and Challenges of Stem Cell Therapy in Regenerative Medicine', Life Stud., vol. 1, no. 1, pp. 70–86, Jan. 2025, doi: 10.71204/wh3nfp64.

[2] K. Takahashi and S. Yamanaka, 'Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors', Cell, vol. 126, no. 4, pp. 663–676, Aug. 2006, doi: 10.1016/j.cell.2006.07.024.

[3] R. J. Lund, E. Närvä, and R. Lahesmaa, 'Genetic and epigenetic stability of human pluripotent stem cells', Nat. Rev. Genet., vol. 13, no. 10, pp. 732–744, Oct. 2012, doi: 10.1038/nrg3271.

[4] 'Screening a large, ethnically diverse population of human embryonic stem cells identifies a chromosome 20 minimal amplicon that confers a growth advantage', Nat. Biotechnol., vol. 29, no. 12, pp. 1132–1144, Nov. 2011, doi: 10.1038/nbt.2051.

[5] European Medicinal Agency, 'GUIDELINE ON HUMAN CELL-BASED MEDICINAL PRODUCTS', European Medicine Agency, London, UK, Guideline EMEA/CHMP/410869/2006, May 2008. Accessed: Apr. 04, 2025. [Online]. Available: https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_entity_is_document%3ADocument&search_api_fulltext=%22Guideline%20on%20human%20cell-based%20medicinal%20products%2C%22

Article by

Akila Wimalasundera

Department of Anatomy, Faculty of Medicine, University of Moratuwa, Sri Lanka.